Fluorine-18 radiopharmaceuticals beyond [18F]FDG for use in oncology and neurosciences

Coenen, Heinz H.; Elsinga, Philip H.; Iwata, Ren; Kilbourn, Michael R.; Pillai, M.R.A.; Rajan, M. G. R.; Wagner, Henry N.; Zaknun, John J.

doi:10.1016/j.nucmedbio.2010.04.185

Cited by 114 publications

(73 citation statements)

References 71 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Secondly, the larger diameter observed might be attributable to the higher positron energy of 68 Ga, which results in a more blurred focus [17,18], which does have a substantial impact on FWHM not only in high-resolution (HR) animal PET imaging [19] but also in state-of-the-art clinical HR-PET systems [20]. As a consequence, techniques for the deblurring of these positron energy-based effects are under evaluation [18].…”

Section: Discussionmentioning

confidence: 99%

Quantification in <sup>68</sup>Ga-DOTA(0)-Phe(1)-Tyr(3)-Octreotide Positron Emission Tomography/Computed Tomography: Can We Be Impartial about Partial Volume Effects?

et al. 2013

View full text Add to dashboard Cite

Aim: In combinedpositron emission tomography/computed tomography (PET/CT) of neuroendocrine neoplasms using ⁶⁸Ga-DOTA(0)-Phe(1)-Tyr(3)-octreotide (⁶⁸Ga-DOTATOC), partial volume effects (PVEs) may occur in smaller lesions. This study determined the lesional cutoff size for the occurrence of PVEs in a clinical setting. Methods: Retrospective assessment of 51 PET/CT examinations (16-slice PET/CT device) for malignant PET foci was carried out. In all foci, the maximal standardized uptake value (SUVmax) and maximal lesion diameter on axial CT was documented. Determined SUVmax and lesional sizes were correlated via LOESS regression. In the resulting curve, the cutoff point for SUVmax size dependency was determined visually and mathematically using 2 approximating straight lines. Results: In 45 patients, 313 of 413 PET foci found were malignant, measurable on CT and had a roughly spherical geometry (SUVmax: 2.5-103.3, mean ± SD 20.5 ± 15.18; CT diameter: 5-103 mm, mean ± SD 21.8 ± 13.1 mm). The cutoff lesional size for the occurrence of PVEs was 20.4 mm by the mathematical approach and 25 mm by visual assessment. Conclusion: In ⁶⁸Ga-DOTATOC imaging, the clinical lesional size threshold is far larger than expected from systemic resolution only. Thus, tracer uptake quantification is only acceptable in sufficiently large lesions.

show abstract

Section: Discussionmentioning

confidence: 99%

Quantification in <sup>68</sup>Ga-DOTA(0)-Phe(1)-Tyr(3)-Octreotide Positron Emission Tomography/Computed Tomography: Can We Be Impartial about Partial Volume Effects?

et al. 2013

View full text Add to dashboard Cite

show abstract

“…Currently, about 90% of all PET studies are performed with FDG [10]. However, because of the limitations discussed above, there is a constant search for new radiopharmaceuticals for oncological PET.…”

Section: Pet Radiotracers Beyond Fdgmentioning

confidence: 99%

Positron emission tomography (PET) in oncology: current applications and future perspectives

Trofimiuk–Müldner¹,

Hubalewska‐Dydejczyk²

2014

Bio-Algorithms and Med-Systems

View full text Add to dashboard Cite

Positron emission tomography (PET), particularly dual-modality imaging systems (PET/CT or PET/MRI), has evolved from being a research tool into a valuable clinical modality, particularly in the field of oncology. Currently, most of the PET/CT examinations are done with FDG when assessing glucose metabolism in tumors. FDG PET or PET/ CT has been proven to be a valuable method in staging, restaging, therapy response assessment, early recurrence detection, and in unknown primary focus localization. However, PET/CT has its limitations, leading to both falsepositive and false-negative results. Proper design and/or choice of an alternative tracer may overcome those problems as well as give better insight into tumor biology and result in more thorough assessment and effective therapeutic approach in patients with cancer.

show abstract

“…[ 18 F]FDG also cannot serve as a companion diagnostic for the discovery, development, and use of new molecular therapeutics. Increasing diversity of tracers beyond [ 18 F]FDG will be needed in the clinic to provide effective diagnostics with more specificity over a greater range of disease and injury (Coenen et al 2010) (Daniels et al 2010). …”

Section: Increasing Diversity Of Petmentioning

confidence: 99%

Emerging Technologies for Decentralized Production of PET Tracers

Keng¹,

Esterby²,

Dam³

2012

Positron Emission Tomography - Current Clinical and Research Aspects

View full text Add to dashboard Cite

Fluorine-18 radiopharmaceuticals beyond [18F]FDG for use in oncology and neurosciences

Cited by 114 publications

References 71 publications

Quantification in <sup>68</sup>Ga-DOTA(0)-Phe(1)-Tyr(3)-Octreotide Positron Emission Tomography/Computed Tomography: Can We Be Impartial about Partial Volume Effects?

Quantification in <sup>68</sup>Ga-DOTA(0)-Phe(1)-Tyr(3)-Octreotide Positron Emission Tomography/Computed Tomography: Can We Be Impartial about Partial Volume Effects?

Positron emission tomography (PET) in oncology: current applications and future perspectives

Emerging Technologies for Decentralized Production of PET Tracers

Contact Info

Product

Resources

About